Prevalence of Fungal Infections in Children with Hematologic Disorders and Determination of Anti-Fungal Susceptibility in Isolated Species


1 Associate Professor, Alborzi Clinical Microbiology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

2 Medical Student, Alborzi Clinical Microbiology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

3 Associate Professor, Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

4 Alborzi Clinical Microbiology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran


Background & Aims: Fungal infections are among the most common life threatening conditions in patients with hematologic malignancies. The present study was carried out on children hospitalized in Amir Oncology Hospital of Shiraz, Iran, in order to determine the prevalence of fungal infections and respective susceptibility patterns to prophylactic antifungal therapies. Methods: Colonization was investigated in patients and the samples from patients with suspected infections were cultured. Mold fungal species were determined using lacto phenol cotton blue smear and yeasts through germ tube test, and sugar fermentation was performed through analytical profile index (API) method. In addition, broth microdilution technique was used to determine susceptibility. Results: Based on the results, 46.8% of all patients (196 patients) were colonized with Candida spp. As revealed, 14 oral candidiasis cases were detected with Candida albicans, Candida tropicalis, and Candida krusieas the respective etiologic agents. In addition, there were 10 proven, 13 probable, and 13 possible cases of fungal infection. The etiologic fungal agents included Candida spp., Aspergillus spp., Mucor, Fusarium, and Alternaria. Conclusion: Considering the prevalence rates of fungal infections and susceptibility patterns of pathogenic fungi isolated from the patients in the region, the prevention and treatment of systemic fungal diseases is facilitated.


  1. Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34(1): 7-14.
  2. Wingard JR, Leather HL. Diagnosis and therapy of invasive aspergillosis in hematopoietic stem cell transplant recipient. Curr Treat Opt Infect Dis 2003; 5: 517-27.
  3. Walsh TJ, Gonzalez C, Lyman CA, Chanock SJ, Pizzo PA. Invasive fungal infections in children: recent advances in diagnosis and treatment. Adv Pediatr Infect Dis 1996; 11: 187-290.
  4. Maschmeyer G, Haas A. The epidemiology and treatment of infections in cancer patients. Int J Antimicrob Agents 2008; 31(3): 193-7.
  5. Chamilos G, Luna M, Lewis RE, Bodey GP, Chemaly R, Tarrand JJ, et al. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). Haematologica 2006; 91(7): 986-9.
  6. Badiee P, Kordbacheh P, Alborzi A, Zakernia M, Haddadi P. Early detection of systemic candidiasis in the whole blood of patients with hematologic malignancies. Jpn J Infect Dis 2009; 62(1): 1-5.
  7. Badiee P, Kordbacheh P, Alborzi A, Zeini F, Mirhendy H, Mahmoody M. Fungal infections in solid organ recipients. Exp Clin Transplant 2005; 3(2): 385-9.
  8. Badiee P, Alborzi A, Davarpanah MA, Shakiba E. Distributions and antifungal susceptibility of Candida species from mucosal sites in HIV positive patients. Arch Iran Med 2010; 13(4): 282-7.
  9. Rippon JW. Medical mycology: the pathogenic fungi and the pathogenic actinomycetes. Philadelphia, PA: Saunders; 1988.
  10. Denning DW. Therapeutic outcome in invasive aspergillosis. Clin Infect Dis 1996; 23(3): 608-15.
  11. NCCLS. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard-second edition [Online]. [cited 2002]; Available from: URL:
  12. Marodi L, Johnston RB. Invasive Candida species disease in infants and children: occurrence, risk factors, management, and innate host defense mechanisms. Curr Opin Pediatr 2007; 19(6): 693-7.
  13. Lopes MM, Barros R, Peres I, Serelha M, Neto MT, Cabrita J, et al. Surveillance of nosocomial fungal infections in a Portuguese paediatric hospital: incidence and risk factors. Journal de Mycologie Médicale / Journal of Medical Mycology 2006; 16(4): 212-9.
  14. Farmaki E, Evdoridou J, Pouliou T, Bibashi E, Panagopoulou P, Filioti J, et al. Fungal colonization in the neonatal intensive care unit: risk factors, drug susceptibility, and association with invasive fungal infections. Am J Perinatol 2007; 24(2): 127-35.
  15. Pasqualotto AC, Nedel WL, Machado TS, Severo LC. A 9-year study comparing risk factors and the outcome of paediatric and adults with nosocomial Candidaemia. Mycopathologia 2005; 160(2): 111-6.
  16. Yeh TC, Liu HC, Wang LY, Chen SH, Liang DC. Invasive fungal infection in children undergoing chemotherapy for cancer. Annals of Tropical Paediatrics 2007; 27: 141-7.
  17. Filioti J, Spiroglou K, Panteliadis CP, Roilides E. Invasive candidiasis in pediatric intensive care patients: epidemiology, risk factors, management, and outcome. Intensive Care Med 2007; 33(7): 1272-83.
  18. Zaoutis TE, Foraker E, McGowan KL, Mortensen J, Campos J, Walsh TJ, et al. Antifungal susceptibility of Candida spp. isolated from pediatric patients: a survey of 4 children's hospitals. Diagn Microbiol Infect Dis 2005; 52(4): 295-8.
  19. Badiee P, Alborzi A. Susceptibility of clinical Candida species isolates to antifungal agents by E-test, Southern Iran: A five year study. Iran J Microbiol 2011; 3(4): 183-8.
  20. White TC, Holleman S, Dy F, Mirels LF, Stevens DA. Resistance mechanisms in clinical isolates of candida albicans. Antimicrob Agents Chemother 2002; 46(6): 1704-13.
  21. Pfaller MA, Messer SA, Hollis RJ, Jones RN, Diekema DJ. In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp. Antimicrob Agents Chemother 2002; 46(6): 1723-7.
  22. Walsh TJ, Adamson PC, Seibel NL, et al. Pharmacokinetics, safety and tolerability of caspofungin in children and adolescents. Antimicrob Agents Chemother 2005;45:4636-45.